NEUROFIT

Illkirch-graffenstaden, France Founded: 1996 • Age: 30 yrs Acquired By Domain Therapeutics
A preclinical CRO specializing in nervous system disorder treatments.

About NEUROFIT

NEUROFIT is a Healthcare company based in Illkirch-graffenstaden (France) founded in 1996, and was acquired by Domain Therapeutics in December 2019. A preclinical CRO specializing in nervous system disorder treatments. It operates on a Professional Services model. Its chief executive, as recorded, is Daniel Ejnes. NEUROFIT offers products and services including Preclinical Testing for CNS Disorders and Preclinical Testing for PNS Disorders. Its focus areas include Biotechnology and Preclinical Research. Its competitors include GenOway and TransCure bioServices; 2 of its 2 listed competitors have raised funding.

Company details

NEUROFIT is a preclinical Contract Research Organization focused on the evaluation of treatments for central and peripheral nervous system disorders. Services are provided through a comprehensive range of in vitro and in vivo models covering indications such as Alzheimers, Parkinsons, epilepsy, and neuropathic pain. Expertise is offered to guide model selection for drug screening and development. Customized experimental designs are adapted to client needs, supporting biopharmaceutical research with cost-effective evaluation methods across neurology, psychiatry, and inflammation sectors.

  • Headquarters Illkirch-graffenstaden, France
  • Stage Acquired
  • Sectors
    Healthcare
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website neurofit.com
  • Social LinkedIn X
  • Acquired by Domain Therapeutics (Dec 2019)
Key Metrics

Products & Services of NEUROFIT

NEUROFIT offers a comprehensive portfolio of products and services, including Preclinical Testing for CNS Disorders and Preclinical Testing for PNS Disorders.

Preclinical Testing for CNS Disorders
Research Services

Services for evaluating treatments for CNS disorders offered.

Preclinical Testing for PNS Disorders
Research Services

Services for assessing treatments for PNS disorders provided.

Investors in NEUROFIT

NEUROFIT has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Domain Therapeutics.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
GPCR-targeted drug candidates for immuno-oncology and inflammation are developed.
2008domaintherapeutics.comStrasbourg, France
Premium access

Investor details for NEUROFIT

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of NEUROFIT

1 people are tracked at NEUROFIT (1 in leadership).

NameRoleGroup
Daniel Ejnes
CEOLeadership
Premium access

Complete people profiles for NEUROFIT

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of NEUROFIT

2 dated milestones of NEUROFIT across 23 years, from founding to its latest funding, stage changes and deals.

  1. Founded NEUROFIT is founded.
  2. Exit Acquired by Domain Therapeutics.

Competitors of NEUROFIT

NEUROFIT has 2 listed competitors in our database, 2 of them funded. They include GenOway and TransCure bioServices.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
genoway.com1999Lyon, France$11.55M
Provider of transgenic rodent models and customized cell lines for preclinical development
transcurebioservices.com2012Archamps, France$3.58M
Humanized mouse models are developed for preclinical immune drug studies.
Premium access

Detailed competitors of NEUROFIT

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of NEUROFIT

The website of NEUROFIT (neurofit.com) receives about 3.5K visits a month.

  • Monthly visits
    3.5K

    ▲ 8.5% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Neurofit

Premium access

Complete news archive for NEUROFIT

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about NEUROFIT

NEUROFIT was founded in 1996.

NEUROFIT is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.

Daniel Ejnes is the CEO of NEUROFIT, as recorded in our data.

NEUROFIT is a preclinical Contract Research Organization focused on the evaluation of treatments for central and peripheral nervous system disorders. Services are provided through a comprehensive range of in vitro and in vivo models covering indications such as Alzheimers, Parkinsons, epilepsy, and neuropathic pain. Expertise is offered to guide model selection for drug screening and development. Customized experimental designs are adapted to client needs, supporting biopharmaceutical research with cost-effective evaluation methods across neurology, psychiatry, and inflammation sectors.

NEUROFIT's top competitors include GenOway and TransCure bioServices.

NEUROFIT offers Preclinical Testing for CNS Disorders and Preclinical Testing for PNS Disorders.

NEUROFIT has 1 investor. Key investors include Domain Therapeutics.

Yes. NEUROFIT was acquired by Domain Therapeutics in December 2019.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available